期刊文献+

中性粒细胞与淋巴细胞比值结合前列腺特异性抗原在前列腺癌早期诊断中的意义 被引量:3

Clinical value of NLR combined with PSA in the early diagnosis of prostate carcinoma
原文传递
导出
摘要 目的:探讨外周血中性粒细胞与淋巴细胞比值(NLR)联合前列腺特异性抗原(PSA)对前列腺癌早期诊断的意义。方法选取内蒙古自治区人民医院行手术治疗的前列腺癌患者120例为研究组,120例健康人群为对照组,检测中性粒细胞与淋巴细胞及 PSA,计算 NLR。运用受试者回归曲线(ROC 曲线)判定NLR 诊断前列腺癌的临界值,并分析 NLR 联合 PSA 对早期诊断前列腺癌的意义。结果运用 ROC 曲线分析NLR 诊断前列腺癌的临界值为2.75,灵敏度为0.79,特异度为0.85,Youden 指数为0.65,准确度为0.72,NLR与 PSA 联合对前列腺癌诊断的灵敏度、特异度、阳性似然比、阴性似然比、Youden 指数分别为0.85、0.83、5.00、0.18、0.68。结论选择 NLR 诊断前列腺癌的敏感性与特异性都提高,NLR 结合 PSA 有助于提高前列腺癌早期诊断的敏感性与特异性。 Objective To discuss the significance of the application of neutrophil to lymphocyte ratio (NLR)combined with prostate specific antigen (PSA)in early diagnosis of prostate carcinoma.Methods 120 cases with surgery treatment of prostate carcinoma were selected as study group,and 120 healthy people were selected as control groups.The NLR and PSA were tested to diagnose the prostate carcinoma.The critical value of NLR in diagnosing prostate carcinoma was evaluated by ROC curves,and the advantages of combination of NLR and PSA were judged. Results By using ROC curves to evaluate the NLR in diagnosis,the critical value was 2.75.The susceptibility, specificity,Youden index,correct index were 0.79,0.85,0.65,0.72.The susceptibility,specificity,positive predictive value,negative predictive value,correct index of NLR combined with PSA in diagnosing the prostate carcinoma were 0.85,0.83,5.00,0.18,0.68.Conclusion The application of NLR has higher susceptibility and specificity to diagnose prostate carcinoma.NLR combined with PSA can improve the susceptibility and specificity of early diagnosis of prostate carcinoma.
出处 《中国基层医药》 CAS 2016年第19期2894-2897,共4页 Chinese Journal of Primary Medicine and Pharmacy
基金 内蒙古自治区科技计划项目(20120403)
关键词 前列腺肿瘤 中性粒细胞与淋巴细胞比值 前列腺特异性抗原 诊断 Prostate neoplasms Neutrophil to lymphocyte ratio Prostate specific antigen Diagnosis
  • 相关文献

参考文献3

二级参考文献35

  • 1潘秀军,沈霞.前列腺特异性抗原比值(游离/总)在前列腺疾病诊断中的应用价值[J].检验医学,2005,20(2):89-91. 被引量:7
  • 2马兴璇,黄慧艳.肿瘤相关物质群检测在肿瘤诊断中的应用[J].检验医学与临床,2007,4(8):739-740. 被引量:19
  • 3Jemal A, Bray F, Center M M, et al, Global cancer statistics [J]. CA Cancer J Clin, 2011 , 61 (2) : 69 - 90.
  • 4Crawford E D. Epidemiology of prostate cancer[J]. Urology, 2003, 62(6 Suppl 1) , 3 -12.
  • 5Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence, and mortality. Part I: international comparisons [J]. BJU Int, 2002, 90 ( 2) : 162 - 173.
  • 6Gronberg H. Prostate cancer epidemiology [J]. Lancet, 2003, 361 (9360) : 859 - 864.
  • 7Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010 [J]. CA Cancer J Clin, 2010, 60(5): 277 -300.
  • 8全国肿瘤防治研究办公室、全国肿瘤登记中心、卫生部疾病预防控制局.中国肿瘤登记年报2004[M].北京:中国协和医科大学,2004:365.
  • 9Mohler J L, Armstrong A J, Bahnson R R, et al, Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines [J]. J Natl Compr Cane Netw, 2012,10(9): 1081 -1087.
  • 10Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer[J]. Eur Urol, 2011 , 59 (4) : 572 - 583.

共引文献15

同被引文献20

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部